Verici Dx plc (AIM:VRCI)
0.7750
+0.1500 (24.00%)
Oct 10, 2025, 5:08 PM GMT+1
Verici Dx Revenue
Verici Dx had revenue of $1.91M USD in the half year ending June 30, 2025, with 9,968.42% growth. This brings the company's revenue in the last twelve months to $1.91M, down -55.85% year-over-year. In the year 2024, Verici Dx had annual revenue of $3.34M with 229.62% growth.
Revenue (ttm)
$1.91M
Revenue Growth
-55.85%
P/S Ratio
8.40
Revenue / Employee
$106.28K
Employees
18
Market Cap
11.73M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
Dec 31, 2023 | 1.01M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Verici Dx News
- 4 days ago - Verici Dx Plc (VRCDF) Interim Results Investor Presentation Call Transcript - Seeking Alpha
- 4 days ago - Verici Dx plc - Special Call - Seeking Alpha
- 5 months ago - AIM Market Roundup: Belluscura, Tiger Royalties, ITM Power - The Armchair Trader
- 6 months ago - AIM Market Roundup: Ethernity Networks, Verici DX, Aferian - The Armchair Trader
- 6 months ago - AIM Market Roundup: Rome Resources, Celadon Pharmaceuticals, Churchill China - The Armchair Trader
- 6 months ago - AIM Market Roundup: Celadon Pharma, Oracle Power, Volex - The Armchair Trader
- 11 months ago - FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians - Business Wire